# Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients

Study · id `cardio:ct-nct06421870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06421870](<https://clinicaltrials.gov/study/NCT06421870>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06421870

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

## Technical summary

Registry record NCT06421870. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT06421870, source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06421870, source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)
- Primary completion: 2025-05 (anticipated) (ClinicalTrials.gov record NCT06421870, source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)
- Completion: 2025-07 (anticipated) (ClinicalTrials.gov record NCT06421870, source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06421870, source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06421870-2024-05-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Pentoxifylline 400 MG
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: 5c9301736c3fc8c6f768e24158e64f8781b1f5061ba47faaf25b8c9665562f60
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
